Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sharps Technology Inc (STSS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: STSS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -65.35% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.81M USD | Price to earnings Ratio - | 1Y Target Price 352 |
Price to earnings Ratio - | 1Y Target Price 352 | ||
Volume (30-day avg) 50939474 | Beta 1.19 | 52 Weeks Range 0.03 - 17.25 | Updated Date 03/30/2025 |
52 Weeks Range 0.03 - 17.25 | Updated Date 03/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -8.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -52.02% | Return on Equity (TTM) -103.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 191069 | Price to Sales(TTM) - |
Enterprise Value 191069 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.19 | Shares Outstanding 1797800 | Shares Floating 1255772 |
Shares Outstanding 1797800 | Shares Floating 1255772 | ||
Percent Insiders 3.7 | Percent Institutions 4.03 |
Analyst Ratings
Rating 5 | Target Price 16 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sharps Technology Inc
Company Overview
History and Background
Sharps Technology, Inc. was founded to revolutionize injection device safety and reduce needlestick injuries. While a specific founding year and detailed milestones are not publicly available without deeper research and access to proprietary information, the company focuses on innovative safety injection technologies.
Core Business Areas
- Sharps SafetyProu00ae: Designs and manufactures safety injection devices featuring automatic retraction and needlestick prevention technology. Focuses on reducing accidental needlestick injuries.
- Sharps MD syringes: Needle safety devices. These syringes are designed to provide safety features for the end user and also helps mitigate product loss.
Leadership and Structure
Information on the specific leadership team and detailed organizational structure requires access to company filings and resources.
Top Products and Market Share
Key Offerings
- Sharps SafetyProu00ae: Safety syringes designed to prevent needlestick injuries. Market share data is not readily available. Competitors include Becton Dickinson (BDX), Smiths Medical (SMIT), and Medtronic (MDT).
- Sharps MD syringes: Needle safety devices. Market share data is not readily available. Competitors include Becton Dickinson (BDX), Smiths Medical (SMIT), and Medtronic (MDT).
Market Dynamics
Industry Overview
The medical device industry is driven by technological advancements, regulatory requirements, and growing healthcare needs. Safety injection devices are increasingly important due to heightened awareness of healthcare worker safety and infection prevention.
Positioning
Sharps Technology aims to be a leader in safety injection technology. Their competitive advantage lies in their proprietary safety mechanisms and focus on reducing needlestick injuries.
Total Addressable Market (TAM)
The global safety syringe market is estimated to be in the billions of dollars. Sharps Technology's position within the TAM depends on its market penetration and sales growth. Data not readily available.
Upturn SWOT Analysis
Strengths
- Proprietary safety technology
- Focus on needlestick prevention
- Potential for high growth in safety-conscious markets
Weaknesses
- Limited brand recognition compared to larger competitors
- Smaller market presence
- Reliance on specific technologies
Opportunities
- Expanding into new markets and geographies
- Partnering with healthcare providers and distributors
- Developing new safety injection devices
Threats
- Competition from established medical device companies
- Regulatory changes and compliance requirements
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- BDX
- MDT
- SMIT
Competitive Landscape
Sharps Technology faces significant competition from established players with greater resources and market share. Their advantage lies in their specialization in safety injection technology, but they need to scale their operations and market reach to effectively compete.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Unavailable due to lack of historical data.
Future Projections: Future projections are unavailable without access to analyst estimates and company guidance.
Recent Initiatives: Requires review of recent company press releases and investor communications.
Summary
Sharps Technology focuses on safety injection devices. Their niche is needlestick prevention, but they face strong competition from larger, more established medical device manufacturers. To thrive, they need to expand their market presence and scale their operations. Success depends on their ability to innovate and gain market share in the safety injection sector.
Similar Companies
- BDX
- MDT
- SMIT
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Financial News Outlets
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share and financial data may not be precise due to limited publicly available information. Ratings are AI-based and subjective. Conduct your own research before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sharps Technology Inc
Exchange NASDAQ | Headquaters Melville, NY, United States | ||
IPO Launch date 2022-04-14 | CEO & Director Mr. Robert M. Hayes | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 57 | Website https://sharpstechnology.com |
Full time employees 57 | Website https://sharpstechnology.com | ||
Sharps Technology, Inc., a medical device company, engages in the design, research and development, manufacturing, and commercialization of safety syringe products in the United States. The company provides safety syringe products comprising Securgard, Sologard, and Sharps Provensa that are ultra-low waste syringes for passive, and safety and reuse prevention features, as well as develops prefillable syringe systems. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.